OIG Greenlights Rare Disease Patient Support Program But Cautions About Emerging IRA Implications

Key Takeaways In Advisory Opinion 26-17, OIG approved a proposed arrangement in which a nonprofit, tax-exempt charitable organization would provide health insurance premium assistance and copayment assistance to patients with rare and chronic diseases, funded in part by pharmaceutical manufacturers. OIG’s analysis rested on traditional safeguards: the requestor’s independence from manufacturer donors; broad disease fund … Continued